Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 44, 2008, Pages 17109-17114

  Kremen, Michal ^a   Krishnan, Ranjini ^a   Emery, Isaac ^a   Jie, Hong Hu ^a   Slezicki, Katherine I ^a   Wu, Alyssa ^a   Qian, Kun ^a   Du, Liang ^a   Plawman, Abigail ^a   Stempien Otero, April ^a   Dichek, David A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

Aneurysm; Aorta; Proteolysis

Indexed keywords

APOLIPOPROTEIN E; PLASMINOGEN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; LIPID STORAGE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CORONARY STENOSIS; MACROPHAGES; MICE; PLASMINOGEN; TRANSGENES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 55949112237     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0808650105     Document Type: Article

References (29)

1. Plow EF, Hoover-Plow J (2004) The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med 14:180-186.
2. Syrovets T, Simmet T (2004) Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 61:873-885.
3. Fay WP, Garg N, Sunkar M (2007) Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 27:1231-1237.
4. Falkenberg M, Björnheden T, Lindnér P, Risberg B (1998) Co-localization of fibrinolytic activators and inhibitors with macrophages in atherosclerotic vessels. Cardiovasc Pathol 7:223-231.
5. Raghunath PN, et al. (1995) Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15:1432-1443.
6. Kienast J, et al. (1998) Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost 79:579-586.
7. Steins MB, et al. (2004) Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 15:383-391.
8. Bachmann F (2001) in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, eds Colman, RW, Hirsh, J, Marder, VJ, Clowes, AW, George, JN (Lippincott, Williams, and Wilkins, Philadelphia), pp 275-320.
9. Ellis V, Behrendt N, Danø K (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752-12758.
10. Folsom AR, et al. (2001) Prospective study of fibrinolytic factors and incident coronary heart disease: The atherosclerosis risk in communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21:611-617.
11. Cushman M, et al. (1999) Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19:493-498.
12. Sakkinen PA, et al. (1999) Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol 19:499-504.
13. Ploplis VA, et al. (1998) Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 91:2005-2009.
14. Torzewski M, et al. (2004) Enzymatic modification of low-density lipoprotein in the arterial wall: A new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 24:2130-2136.
15. Carmeliet P, et al. (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17:439-444.
16. Xiao Q, et al. (1997) Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 94:10335-10340.
17. Cozen AE, et al. (2004) Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 109:2129-2135.
18. Blasi F, Carmeliet P (2002) uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943.
19. Tsirka SE, et al. (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 17:543-552.
20. Kim Y-H, Park J-H, Hong SH, Koh J-Y (1999) Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284:647-650.
21. Naldini L, et al. (1992) Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11:4825-4833.
22. Hu K, Wu C, Mars WM, Liu Y (2007) Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 3821-3832.
23. Fuhrman B, et al. (2007) Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis 195:e108-116.
24. Carmeliet P, et al. (1997) Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 99:200-208.
25. Moons L, et al. (1998) Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest 102:1788-1797.
26. Otsuka G, Stempien-Otero A, Frutkin AD, Dichek DA (2007) Mechanisms of TGF-beta1-induced intimal growth: Plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ Res 100:1300-1307.
27. Boucher P, et al. (2003) LRP: Role in vascular wall integrity and protection from atherosclerosis. Science 300:329-332.
28. Hume DA, Gordon S (1983) Optimal conditions for proliferation of bone marrow-derived mouse macrophages in culture: The roles of CSF-1, serum, Ca2+, and adherence. J Cell Physiol 117:189-194.
29. Stempien-Otero A, et al. (2006) Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 281:15345-15351.